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Abstract. There were ~986,000 cases of head and neck cancer 
(HNC) and oesophageal cancer diagnosed worldwide in 2012. 
The incidence of these types of cancer is much higher in males 
than females, although this disparity decreases in the elderly 
population, suggesting a role for hormones as a risk factor. 
This systematic review investigates the potential role of female 
hormones [age at menopause and use of hormone replacement 
therapy (HRT)] as risk factors for HNC/oesophageal squamous 
cell carcinoma (SCC). The electronic databases MEDLINE, 
Web of Science, EMBASE and Cochrane were searched. Only 
studies with at least 50 cases of HNC/oesophageal SCC, with 
data on age at menopause, smoking, alcohol, age and socio-
economic status or educational attainment, were included. The 
Newcastle Ottawa Scale was used for assessing risk of bias. 
Eight studies met the inclusion criteria (5 oesophageal SCC, 
2 HNC and 1 combined oesophageal SCC and HNC). HRT 
was shown to reduce the risk of HNC (HR, 0.78; 95% CI, 0.61-
0.99) in one study. Our results showed that earlier age at 
menopause is a risk factor for oesophageal SCC, with women 
entering menopause at <45 years having double the risk of 
those entering menopause at age >50 years. Similar, but less 
striking, results were observed for HNC. HRT was found to 
reduce the risk of HNC/oesophageal SCC, but the evidence 
is inconclusive. We, therefore, recommend that consideration 
should be given to collecting data on reproductive factors and 
exposure to HRT, as routine practice, in future epidemiological 
and clinical studies of these cancers. The concept of oestrogen 
deficiency as a risk for HNC/oesophageal SCC deserves 
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1. Introduction
There were ~986,000 cases of head and neck cancer (HNC), 
and oesophageal cancer diagnosed worldwide in 2012. In the 
same year, in the UK, there were 5,000 cases of HNC in males 
and 2,500 in females (1). In 2013, there were 8,784 cases of 
oesophageal cancer, with a male:female ratio of 2:1. This 
makes HNC and oesophageal cancer the 12th and 13th most 
common cancers in the UK (2). The ratio of male:female cases 
of HNC in persons aged 50-60 years is ~3:1, however, the 
gender disparity is reduced in the elderly population, with 
a male female ratio of 1.5:1 in individuals over 80 years of 
age (3). For oesophageal squamous cell carcinoma (SCC) the 
male:female ratio is lower, at 1.1:1.
Understanding the differences between subgroups of the 
population is important to ensure that policy makers can make 
informed decisions regarding preventive measures. Smoking 
and alcohol are the major risk factors for HNC and oesopha-
geal SCC; however, the differences in incidence between 
age categories cannot be solely attributed to differences in 
smoking and alcohol consumption (4). Hormones are known 
to play an important role in several types of cancers, such as 
breast, ovarian and uterine, endometrial, prostate, testis and 
thyroid cancers.
Studies have been carried out on hormone-related risk 
factors for squamous cancers, such as oesophageal, cervical 
and lung cancer (5). While hormone replacement therapy 
(HRT) is a known risk factor for certain cancers (e.g. breast 
cancer), a recent meta-analysis found that the use of HRT is 
protective against oesophageal SCC (6). Early-menopause 
has also been linked to an increased risk of oesophageal SCC 
[risk ratio (RR), 1.32 (95% CI, 1.11-1.56)/5 years younger at 
menopause] (7). Another meta-analysis suggested decreased 
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risk of lung cancer in never-smoker females who use HRT 
[OR, 0.86 (95% CI, 0.75-0.99)]. This leads to the hypothesis 
that hormone levels may be a potential risk factor for squa-
mous cancers. There is uncertainty surrounding the role of 
female hormones and the risk of head and neck oesophageal 
SCC. However, to the best of our knowledge, no systematic 
review has been conducted to address this uncertainty. The 
aim of this systematic review was to address the uncertainty 
surrounding the role of female hormones and the risk of head 
and neck and oesophageal SCC by evaluating two specific 
questions: i) is early menopause a risk factor for HNC or 
oesophageal SCC and ii) is HRT protective against HNC or 
oesophageal SCC?
2. Methods
In the present study, we combined head and neck, and oesopha-
geal SCC due to their histology and strong similarities in their 
epidemiology and aetiology.
Search strategy. Electronic databases MEDLINE, Web of 
Science, EMBASE and Cochrane were searched up until 
February 11, 2016. Search strategies were developed using 
Medical Subject Heading (MeSH) words such as: head and neck 
neoplasms, head and neck and oesophageal cancer, esophageal 
neoplasms, HRT, female hormone, early menopause and text 
words related to hormones and HNC or (o)esophageal cancer. 
Only search terms describing the association were used. 
Reference lists were also extensively searched and relevant 
papers obtained.
Eligibility criteria. Randomized controlled trials (RCTs), 
controlled (non-randomised) clinical trials (CCTs) or cluster 
trials, prospective and retrospective comparative cohort 
studies, case-control or nested case-control studies, and 
cross-sectional studies, addressing the question of female 
hormones as a risk factor for HNC or oesophageal SCC, were 
considered. Studies were included when they: i) examined the 
general adult population (age >18 years), specifically patients 
with at least 50 cases of HNC/oesophageal SCC and healthy 
controls; ii) addressed the question of HRT or reproductive 
factors (menopause) and HNC/oesophageal SCC; iii) admin-
istered HRT as an intervention for prevention of cancer or 
being therapeutically taken due to symptoms of menopause; 
iv) collected data on age at menopause, smoking, alcohol, 
age and socioeconomic status or educational attainment; and 
v) reported odds ratios, risk ratios or incidence/prevalence of 
HNC or oesophageal SCC defined using the World Health 
Organisation (WHO) classification of diseases ICD-10 codes, 
C00-15 and C30-31.
Cohort studies were only eligible when follow-up time was 
at least 5 years; case series and case reports were excluded. 
Only English language articles published in peer-reviewed 
journals, from 1948 to 2016, were considered.
Data extraction. Titles and/or abstracts of studies retrieved 
using the search strategy and those from additional sources 
were independently screened by two review authors (C.M. 
and M.M.), to identify studies that potentially met the inclu-
sion criteria outlined above. Studies combining HNC with 
oesophageal squamous cell cancers were considered, but 
data were extracted to separate HNC and oesophageal cancer 
where possible. Data were extracted in all forms (e.g. dichoto-
mous, continuous) as reported in the included studies. The full 
texts of these potentially eligible studies were independently 
assessed for eligibility by C.M. and M.M. Any disagreement 
over the eligibility of particular studies was resolved through 
discussion with a third reviewer (J.K.F.).
Risk of bias. The risk of bias was assessed using the Newcastle 
Ottawa Scale which includes the following areas of evalua-
tion of the risk of bias: selection of patients, comparability of 
groups in the study, methods for assessing outcomes, proof of 
exposure and appropriate follow-up. Studies were categorised 
as low, medium, high or unclear risk of bias, using a star-based 
scoring system. A maximum of 9 stars are available; the higher 
the number of stars the lower the risk of bias. For ease of 
interpretation, a score of 7 or greater is considered ‘low-risk’ 
of bias, 4-6 is ‘medium-risk’ and 3 or below is considered 
‘high-risk’ of bias.
3. Search results
The search identified 13 potentially eligible studies following 
the review of titles and abstracts of studies identified from the 
initial search. One study considered HNC and oesophageal 
cancer separately, therefore was included in both arms of the 
review. Five papers were excluded, based on insufficient number 
of cases (n=2), failure to report an effect estimate/confidence 
intervals (n=2) and lack of categorisation by histopathological 
subtype (n=1). Eight studies met the inclusion criteria (4,7-13). 
The literature search results and selection process are depicted 
in Fig. 1A and B.
The systematic review includes two cohort studies (one 
oesophageal/HNC and one oesophageal cancer only) (7,8) 
with follow-up time of 7.5 and 9.1 years, respectively. Six 
case-control studies (4 oesophageal cancer and 2 HNC) (4,9-13) 
were also included. Studies covered the UK (7,13), USA (4,8), 
European continent (9,14) and China (11,12). The mean number 
of cases/study for the HNC articles was 214 (range 149-297). 
For oesophageal cancer, the average case number/study was 
163 (range 56-578). A summary of the demographic data for 
each study is presented in Table I. A summary of the findings 
regarding use of HRT and risk of HNC/oesophageal SCC 
is shown in Table IIA. Table IIB summarises the findings 
regarding age at menopause.
4. Hormone replacement therapy (HRT)
HNC. Three papers (1 cohort study and 2 case-control studies) 
addressed the question of the use of HRT and incidence of 
HNC. Only the study by Freedman et al (8) was considered at 
‘low-risk’ of bias, with a Newcastle Ottawa score of 7/9 stars. 
This was a cohort study conducted in the USA, using the 
NIH-AARP Diet and Health Cohort, of 125,887 women. Two 
hundred and ninety-seven cases of HNC were identified with 
mean follow-up of 7.5 years. The risk of HNC was 22% lower 
for ever-users of HRT (HR, 0.78; 95% CI, 0.61-0.99); 44.1% 
of cases (n=127) had ever-used HRT compared to 54.6% of 
controls (n=106,934). Further analysis by hysterectomy status 
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revealed that the risk reduction was greatest for women with 
an intact uterus who were current users of HRT for >5 years 
(HR, 0.23; 95% CI, 0.09-0.57). Notably, use of HRT other than 
oestrogen-alone or oestrogen-progesterone therapy conferred 
a greater risk of HNC (HR, 2.31; 95% CI, 1.15-4.65); however, 
this analysis was based on only 9 cases who used an alter-
native HRT. Two case-control studies were considered at 
medium/high risk of bias; they reported a non-significant 
reduction in the risk of HNC for ever-users of HRT (4,9).
Oesophageal SCC. Four studies analysed HRT use and the 
risk of oesophageal SCC. Two were considered low-risk of 
bias (8,13) and two were medium/high risk of bias (10,11). 
Although, all studies reported an effect estimate of <1 for 
users of HRT, implying a protective effect, none of the results 
were statistically significant.
5. Age at menopause
HNC. Two studies (8,9) assessed the link between age at 
menopause and risk of HNC. Bosetti et al (9) found a protec-
tive effect of later age at menopause (>50 years), with an OR 
of 0.46 (95% CI, 0.30-0.70). Freedman et al (8) found no 
significant effect on the risk of HNC with later age at meno-
pause (>55 years).
Oesophageal SCC. Four out of 5 studies reported a significant 
effect of age at menopause and risk of oesophageal SCC. The 
Figure 1. (A) Flow diagram of literature search results and selection process for head and neck cancer. (B) Flow diagram of literature search results and 
selection process for oesophageal cancer.
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method of reporting varied. Gallus et al (10) reported an OR 
of 0.43 (95% CI, 0.22-0.83) for age at menopause of >50 years 
vs. menopause at age <45 years. Yu et al (11) reported an 
increased risk of oesophageal SCC for women entering 
menopause at <45 years (OR, 2.27; 95% CI, 1.03-4.97) and 
for 45-49 years (OR, 2.16; 95% CI, 1.14-4.78) compared to 
menopause at age >50 years. Green et al (7) reported increased 
risk of oesophageal SCC for every 5 years younger a women 
was at the time of menopause (RR, 1.32; 95% CI, 1.11-1.56). 
Although, Freedman et al (8) found no significant effect for 
individual age categories, they did observe a significant trend 
(p=0.019) for a lower risk of oesophageal SCC with older age 
at menopause. Chen et al (12) observed no significant effect for 
age at menopause, although these authors classified older age 
at menopause as >48 years.
6. Discussion
This systematic review has considered evidence from 
8 studies investigating the risk of head and neck cancer 
(HNC) or oesophageal squamous cell carcinoma (SCC) in 
relation to age at menopause and use of hormone replace-
ment therapy (HRT); 5 studies investigated oesophageal 
SCC, 2 studies investigated HNC and 1 study included both 
cancers.
Early menopause. We found that earlier age at menopause is 
associated with a higher risk of oesophageal cancer, based on 
4 studies with a total of 836 cases of oesophageal SCC.
Most women experience menopause between the ages of 
45 and 55 years; the median age at menopause is 47.2 years, 
according to a prospective cohort study of over 5,000 women 
enrolled at the Royal College of GP's Oral Contraception 
study (15). Menopause is considered to be early in women 
aged 40-45 years (~5% of women) and premature in women 
<40 years (~1% of women) (16).
Early menopause is more frequent in women with certain 
genetic or autoimmune disorders, infections or a history of 
chemotherapy/radiotherapy or surgery to remove the ovaries (16).
Mean age of menopause for smokers is significantly lower 
than non-smokers (45.6 vs. 46.9 years) (15). Women with early 
natural menopause are more likely to be smokers, ever-users 
Table I. Demographic characteristics of the included studies.
First author (year) (ref.) Country Study type Cancer type Participant demographics Time period
Freedman (2010) (8) USA Cohort HNC/ NIH-AARP Diet and Health Study cohort, 1995-2003
   oesophageal aged 50-71 years
    (median follow-up 7.5 years)
Langevin (2011) (4) USA Case-control HNC Cases of primary HNC and complaint-free 2006-2010
    hospital controls at ENT Department,
    University of Pittsburgh Medical Center
Bosetti (2000) (9) Italy/ Case-control HNC Cases of histologically confirmed oral/ 1984-1997
 Switzerland   pharyngeal cancer age <75 years attending
    hospitals in Italy/Switzerland and hospital
    controls with acute, non-neoplastic conditions
Lindblad (2006) (13) UK Nested Oesophageal UK General Practice Research Database 1994-2001
  case-control  (UK GPRD) cohort aged 50-84 years
Gallus (2003) (14) Italy/ Case-control Oesophageal Cases aged <79 years with histologically 1984-1999
 Switzerland   confirmed oesophageal SCC admitted to
    study hospitals; hospital controls
    admitted to the same hospitals
    for acute, non-neoplastic conditions
Yu (2011) (11) China Case-control Oesophageal Cases of histopathologically confirmed 2008-2010
    oesophageal SCC; hospital based
    controls confirmed not to have
    oesophageal cancer
Chen (2011) (12) China Case-control Oesophageal Cases of newly diagnosed primary 2004-2010
    oesophageal cancer; hospital controls
    with no history of cancer
Green (2012) (7) UK Cohort Oesophageal Million Women Study cohort 1996-2008
    (women aged 50-64 years)
    with mean 9.1 years follow-up
HNC, head and neck cancer.
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of oral contraceptive medication, undergone tubal ligation, 
have at least one episode of endometriosis and are less likely 
to use HRT. No association with alcohol, BMI, physical 
activity or parity was reported (15). Diabetic women have 
also been found to be at risk of early menopause (OR, 2.76; 
95% CI, 1.32-5.66) (17). In a pooled analysis of case-control 
studies, diabetes diagnosed at age <50 years conferred a greater 
risk of HNC (OR, 1.37; 95% CI, 1.07-1.74) when analysing 
6,448 cases of HNC and 13,747 controls (18), but no link with 
age at menopause was considered in the present study.
A recent systematic review and meta-analysis of oesopha-
geal SCC and reproductive factors also found a protective effect 
for older age at menopause (SRR=0.70; 95% CI, 0.51-0.95). 
The authors concluded that ‘properly extending the time of 
menstruation for pre-menopausal women is a possible way to 
reduce the risk of oesophageal SCC’ (19). A separate meta-
analysis found that menopausal status was associated with 
higher risk of oesophageal SCC (RR, 1.66; 95% CI, 1.12-2.48), 
but age at menopause was not significant for Caucasians. In 
Asians, older age at menopause was found to confer greater risk 
of oesophageal SCC (RR, 1.68; 95% CI, 1.05-2.70) (6). This 
implies that ethnicity and genetic background may influence 
the role of female hormones in oesophageal carcinogenesis.
The effect of age at menopause has been explored in several 
other cancer types. A meta-analysis of 8 studies of gastric 
cancer and reproductive factors found a protective effect of 
longer years of fertility (RR=0.74; 95% CI, 0.63-0.86) (20). 
Early menopause has also been found to be a risk factor for 
bladder cancer (meta-analysis including 7 studies: RR=1.59; 
95% CI, 1.31-1.92) (21). Two studies from Hungary, from 
the same unit, found that the mean age at menopause was 
significantly lower in females with oral cancer compared to 
controls (43.5 vs. 50.9 and 45.4 years vs. 51.3 years, respec-
tively) (22,23). These studies were excluded from this review 
due to the failure to provide accurate effect estimates with 
confidence intervals. Other recent meta-analyses found no 
significant effect of age at menopause in relation to risk of 
brain tumours (24), pancreatic (25) or thyroid cancer (26). A 
large cohort study found no association with age at menopause 
and risk of colorectal cancer (27).
Table II. The use of hormone replacement therapy and risk of HNC/oesophageal SCC, and age at menopause and risk of 
HNC/oesophageal SCC.
A, The use of hormone replacement therapy and risk of HNC/oesophageal SCC
      Risk of Bias
   No. of Relative effect  (Newcastle
Outcome of interest First author (year) (ref.) Type of study cases (OR or HR) 95% CI Ottawa Scale)
HNC Freedman (2010) (8) Cohort 297 HR 0.78 0.61-0.99 Low (8/9)
HNC Langevin (2011) (4) Case-control 149 OR 0.47 0.20-1.08 Medium (6/9)
HNC Bosetti (2000) (9) Case-control 195 OR 0.88 0.45-1.72 Medium-high (4/9)
Oesophageal SCC Lindblad (2006) (13) Nested case-control 74 OR 0.93 0.40-2.16 Low (9/9)
Oesophageal SCC Gallus (2001) (10) Case-control 114 OR 0.32 0.09-1.13 Medium-high (4/9)
Oesophageal SCC Freedman (2010) (8) Cohort 56 HR 0.74 0.42-1.26 Low (8/9)
Oesophageal SCC Yu (2011) (11) Case-control 88 OR 0.94 0.53-1.70 Medium-high (4/9)
Bold text denotes a statistically significant result.
B, Age at menopause and risk of HNC/oesophageal SCC
       Risk of Bias
   No. of Age Relative effect  (Newcastle
Outcome of interest First author (year) (ref.) Type of study cases (years) (OR or HR) 95% CI Ottawa Scale)
HNC Freedman (2010) (8) Cohort 297 >55 HR 0.92 0.50-1.71 Low (8/9)
HNC Bosetti (2000) (9) Case-control 195 >50 OR 0.46 0.30-0.70 Medium-high (4/9)
Oesophageal SCC Gallus (2001) (10) Case-control 114 >50 OR 0.43 0.22-0.83 Medium-high (4/9)
Oesophageal SCC Freedman (2010) (8) Cohort 56 Increasing Ptrend=0.019  Low (8/9)
    age
Oesophageal SCC Yu (2011) (11) Case-control 88 <45 OR 2.27 1.03-4.97 Medium-high (4/9)
Oesophageal SCC Green (2012) (7) Cohort 578 Per 5 years RR 1.32 1.11-1.56 Low (7/9)
    younger
Oesophageal SCC Chen (2011) (12) Case-control 68 >48 OR 0.94 0.31-2.85 Medium (5/10)
HNC, head and neck cancer; SCC, squamous cell carcinoma; OR, odds ratio; HR, hazard ratio; CI, confidence interval; RR, risk ratio. Bold text denotes 
a statistically significant result.
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HRT. HRT is long-established in the management of the 
symptoms of the menopause and has also been shown to 
reduce the risk of osteoporotic fractures, cardiovascular 
disease, Alzheimers, depression, stroke and colon cancer. 
Approximately 30% of UK women used HRT in 2001-
2002 (28). Following this, a large US-based trial (Women's 
Health Initiative) was prematurely halted due to concerns 
over the evidence of increased risk of breast cancer, coronary 
heart disease, stroke and pulmonary embolism among users 
of HRT (29). The UK-based Million Women Study (MWS) 
also reported increased risk of breast cancer with HRT in 
2003 (30). Following media coverage of the results of these 
trials, use of HRT declined steadily in the UK for the next 
3-4 years. In 2005, only 10-11% of menopausal women were 
using HRT (28). Further reports of a slight increased risk of 
ovarian cancer for ever-users of HRT compounds enhanced 
concerns over the safety of HRT (31).
However, concerns have been raised by some authors 
surrounding the reporting of the WHI and MWS trial results, 
and the fact that little coverage was given to the evidence of 
the reduced incidence of osteoporotic fractures and colon 
cancer (32). Both trials recruited women aged over 50 years; 
therefore, the results cannot be applied to women who undergo 
premature menopause (33). HRT for women with premature 
menopause (primary ovarian insufficiency), prescribed up to 
the age of natural menopause (~51 years), is endorsed by the 
British Menopause Society and NICE guidelines. The NICE 
guidelines also recommend the development of a collaborative 
'primary ovarian insufficiency' registry to allow data collection 
to clarify, among other factors, the long-term risk of cancers 
in this group (34).
Despite reports of an increased risk of breast and ovarian 
cancers in certain groups using HRT, there are many obser-
vational studies reporting a reduced risk of other cancers in 
HRT users. There are several reports of a reduced risk of colon 
cancer with HRT (27,35,36). Green et al reported a relative risk 
reduction of 17% (RR, 0.83; 95% CI, 0.79-0.88) in their meta-
analysis of 30 studies of colorectal cancer and HRT (36). In a 
recent meta-analysis of oesophageal cancer and reproductive 
factors, the authors reported a 33% relative risk reduction with 
HRT use (SRR, 0.67; 95% CI, 0.56-0.81) (19). Similar results 
were reported for reduced risk of gastric cancers (RR, 0.77; 
95% CI, 0.64-0.92) (20). Combined HRT (oestrogen and proges-
terone) has also been shown to reduce the risk of lung cancer, in 
a meta-analysis of 25 studies (RR, 0.83; 95% CI, 0.76-0.91) (37). 
HRT has not been found to significantly reduce the risk of mela-
noma or pancreatic cancer (25,38).
This systematic review did not find evidence of a significant 
risk reduction for oesophageal cancer among users of HRT, in 
contrast to the findings of the meta-analysis by Zhu et al (19). 
However, all effect estimates were <1 and the studies included 
contained only modest numbers of oesophageal cancer cases. 
The Freedman et al (8) cohort study included 297 cases of 
HNC and was the only study to report a significant rela-
tive risk reduction for HNC in users of HRT (HR, 0.78; 
95% CI, 0.61-0.99). Further large studies are needed to confirm 
the finding that HRT is protective against HNC.
Confounding factors must be considered. Users of HRT 
tend to be of higher socioeconomic status (SES) and have 
higher levels of education. Both of these factors may reduce 
the risk of HNC. To address this, only studies controlling for a 
measure of SES or education were eligible for inclusion in this 
review. Freedman et al (8) controlled for education, alcohol, 
BMI, tobacco smoking, physical activity and diet (fruit and 
vegetable intake), although residual confounding factors could 
still be relevant.
Role of oestrogen deficiency. Females have been found to have 
survival advantage for HNC, oesophageal, gastric and pancre-
atic cancer, as well as cancers at 11 other sites. For all cancers 
combined, women have a 5% lower risk of death than men; for 
HNC, a 12% increased survival is reported (39). This finding is 
consistent across all European regions in the EUROCARE-4 
cohort of 1.6 million population-based cancer cases (39). The 
advantage is most pronounced in younger women and declines 
with age, with a marked decline beyond the age of menopause. 
It is possible that female hormones play a part in this 12% 
improvement in survival.
Oestrogen is known to promote cancer in oestrogen-respon-
sive tissues, such as breast, endometrium and cervix; however, 
evidence from mouse models suggests that oestrogen has an 
inhibitory role in oesophageal SCC growth (40). Oestrogen 
receptors have been found in oesophageal SCC tissue samples 
and HNCs (40-42). Oesophageal SCC cells with oestrogen 
receptors have been shown to be inhibited by oestrogen exposure 
and this may initiate apoptosis (43). If oestrogen is responsible 
for inhibiting the growth of some cancer cells, oestrogen defi-
ciency could be considered a risk factor for certain cancers. 
A women who undergoes premature menopause has less 
oestrogen exposure over her lifetime and this may increase her 
risk of cancers such as oesophageal SCC. However, oestrogen 
appears to have both tumorigenic and antitumour properties, 
depending on the tissue and presence of oestrogen receptors. 
HNC cell lines, from males and females, have been found to 
contain oestrogen receptors, and laboratory studies appear to 
show that oestrogen promotes the growth of HNC cells (44,45). 
Further high quality basic science studies are required to 
confirm the role of oestrogen in HNC and oesophageal SCC.
The studies included in this review were all assessed for 
risk of bias, using the Newcastle Ottawa Scale. Only 3 of the 
8 studies included were low risk for bias. This does limit the 
significance of our findings and is an indication of the need 
for further, high quality, studies addressing the issue of female 
hormones and squamous cancers.
We only included studies that controlled for significant 
potential confounding factors, such as smoking and socio-
economic status, however, the risk of residual confounding 
factors remains. Smokers undergo menopause at a younger age 
than non-smokers. We recommend that future studies should 
control for this important confounder.
The rationale for combining HNC and oesophageal SCC 
is based on the strong similarities in their epidemiology and 
aetiology as mentioned earlier. We deliberately excluded 
oesophageal adenocarcinomas as these cancers have quite 
different aetiology. One of the studies included in our review 
by Bosetti et al (9) failed to clarify the histology of the 
oral/pharyngeal cancer cases included, which introduces a 
potential source of bias. However, over 90% of oral cancers and 
>80% of pharyngeal cancers are of squamous histology (46), 
therefore the bias is unlikely to be significant.
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We found that earlier age at menopause is a risk factor 
for oesophageal SCC, with women entering menopause at 
<45 years having double the risk of those entering meno-
pause at age >50 years. Similar, but less striking, results were 
observed for HNC. HRT was found to reduce the risk of 
HNC/oesophageal SCC, but the evidence is inconclusive. We 
used strict eligibility criteria and only considered studies that 
controlled for other risk factors, however, there is still the risk 
of residual bias. Consideration should be given to collecting 
data on reproductive factors and exposure to HRT, as routine 
practice, in future epidemiological and clinical studies of 
these cancers. The concept of oestrogen deficiency as a risk 
for HNC/oesophageal SCC warrants further investigation in 
future laboratory and clinical studies.
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